NCT06455046 2024-06-12Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical CancerFujian Cancer HospitalPhase 2 Recruiting37 enrolled
NCT06063018 2023-10-02RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical CancerPeking Union Medical College HospitalPhase 2 Recruiting30 enrolled